Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study
Yasir J Sepah, Mohammad Ali Sadiq, David Boyer, David Callanan, Ron Gallemore, Michael Bennett, Dennis Marcus, Lawrence Halperin, Muhammad Hassan, Peter A Campochiaro, Quan Dong Nguyen, Diana V Do
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2016
The author(s) have made the following disclosure(s): Y.J.S.: Consultant - Genentech, Astellas; Research support - Genentech.R.G.: Other - Genentech, pSivida, Allergan, Alcon, Allergan, Bausch & Lomb; Research Support - Genentech, pSivida, Allergan; Speaker - Alcon, Allergan, Bausch & Lomb.D.M.: Advisory board member and consultant - Genentech, Regeneron, Thrombogenics; Clinical research support - Genentech, Regeneron, Thrombogenics.P.A.C.: The George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience; Institutional consulting agreements - Genentech/Roche, Regeneron, Aerpio Therapeutics; Consultant - Alimera, Applied Genetic Technologies, AsclipiX, Rxi, Allegro, Intrexon, Regenxbio; Research support - AbbVie, Alimera, Allergan, Aerpio Therapeutics, Genentech/Roche, Genzyme, GlaxoSmithKline, Oxford Biomedica, Regeneron, Regenxbio, Rxi; Equity interest -Alimera, Allegro, Graybug; Royalties - Graybug. These activities are being managed by the Conflict of Interest Committee of the Johns Hopkins University School of Medicine.Q.D.N.: Recipient of the Physician Scientist Award from Research to Prevent Blindness (New York, NY); Consultant - Santen; Research support - Genentech, Santen, Ophthotech, Regeneron; Institutional consulting agreement - AbbVie; Honorarium - Bayer, XOMA; Chairs the Steering Committee for the RISE and RIDE Studies; Steering Committee - VISTA Study and other studies sponsored by Genentech and Regeneron.D.V.D.: Consultant - Genentech, Regeneron, Santen, Allergan; Research support - Genentech, Regeneron, Santen; Chairs the Steering Committee for the VISTA Study.READ-3 was an investigator-sponsored study with the investigative new drug for the study held by one of the investigators (Q.D.N.). The READ-3 Study was funded by JDRF International, with the study drug provided by Genentech, Inc.